699
Views
0
CrossRef citations to date
0
Altmetric
Research Article

The significance of surveillance imaging in children with Ewing sarcoma and osteosarcoma

ORCID Icon, , ORCID Icon & ORCID Icon
Pages 273-282 | Received 03 Oct 2023, Accepted 24 Jan 2024, Published online: 12 Feb 2024
 

Abstract

Primary bone tumors in children and adolescents, while rare, pose significant challenges in diagnosis and management. Children treated for Ewing sarcoma and osteosarcoma are offered a 5-year follow-up program after end of treatment, including radiological surveillance of primary location of tumor and the lungs. There is no consensus regarding how often and how the children should be followed with radiological imaging. This retrospective descriptive study of 69 patients (34 with Ewing sarcoma and 35 with osteosarcoma) investigated the consequences of abnormal findings in 1279 follow-up images. Nine relapses were detected, 4 in the Ewing group (3 local and 1 pulmonary) and 5 in the osteosarcoma group (1 local and 4 pulmonary). Of these, only two patients exhibited symptomatic relapses, with the remainder identified through imaging. The positive predictive value for relapse detection was 0.44 in the Ewing group, and 0.5 in the osteosarcoma group. In the Ewing sarcoma patient image follow-up program, the probability of anomaly detection was 12% (95% CI, 10–15). For osteosarcoma patients, the likelihood was 6% (95% CI, 4–8). Our data indicates that abnormal findings on follow-up images rarely represents relapse of tumor. As the surveillance protocol differs between the patient groups, wherein Ewing sarcoma patients primarily are monitored through MRI while osteosarcoma patients are predominantly tracked via X-rays, there is an increased occurrence of incidental findings in the first group. However, it is imperative to interpret imaging data in conjunction with clinical information, avoiding isolated reliance on imaging results when making treatment decisions.

Disclosure statement

The authors declare no conflict of interests and have received no funding for the study.

Institutional review board statement

The Danish Patient Safety Authority, case number 31-1521-373 approved the study and did not require Informed Consent Statement from the patients.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.